Dose Response to Recombinant Factor VIIa When Administered for Bleed
Novo Nordisk A/S
This trial is conducted in the United States of America (USA). The purpose of this trial is
to investigate the dose response to recombinant factor VIIa in healthy volunteers when
administered for bleed.
Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
Novo Nordisk A/S
This trial is conducted in Africa, Asia, Europe, South America, and the United States of
The purpose of this study is to evaluate the effectiveness of secondary prophylactic
treatment with NovoSeven® in haemophilia A and B patients with inhibitors.
This trial is conducted in the United States of America (USA). This study compares the
effectiveness and safety of NovoSeven® to FEIBA (FEIBA VH) in haemophilia patients with
inhibitors being treated for joint bleeds.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.